neuroClues is ISO27001:2022 certified ensuring the security of patient & hospital data
Since April 3rd 2026 neuroClues is certified ISO27001:2022 for Information Security Management Systems by AFNOR. This ce …
Prof. Dr. Lafosse and RevArte Featured in Belgian Media for Integrating neuroClues® in Neurorehabilitation
At RevArte in Edegem, clinicians are exploring how eye movements can reveal neurological disorders years before symptoms …
JOIN THE ADVENTURE: Become a neuroClues Shareholder
Brussels, 27 January 2026 — Today, we at P3lab (doing business as neuroClues) are launching our crowdfunding campaign on …
Clinical Get Together 2024 – Recap
Clinical Get Together 2024 - Recap Welcome to the recap of our recent scientific evening, held in conjunction with the J …
neuroClues® secures €5 million to launch its groundbreaking technology, set to support the early diagnosis of Parkinson’s disease and other neurological disorders
neuroClues® secures €5 million to launch its groundbreaking technology, set to support the early diagnosis of Parkinson’ …
ISO 13485:2016 certification for design & development
In summary P3Lab, a European startup founded in 2020 is developing NeuroClues®, a medical device based on eye tracking t …
P3Lab raises 4.2 million euros
In summary P3Lab, a European startup founded in 2020 by former IBA and ICM employees is developing a medical device (Neu …
